EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Protein‐Templated Ugi Reactions versus In‐Situ Ligation Screening: Two Roads to the Identification of SARS‐CoV‐2 Main Protease Inhibitors

Rebekka Wamser, Xinting Zhang, Benno Kuropka, Christoph Arkona, Jörg Rademann iD

Chemistry – A European Journal · 2024

DOI: 10.1002/chem.202303940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Rebekka Wamser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str.2+4, 14195, Be…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein‐templated fragment ligation was established as a method for the rapid identification of high affinity ligands, and multicomponent reactions (MCR) such as the Ugi four‐component reaction (Ugi 4CR) have been efficient in the synthesis of drug candidates. Thus, the combination of both strategies should provide a powerful approach to drug discovery. Here, we investigate protein‐templated Ugi 4CR quantitatively using a fluorescence‐based enzyme assay, HPLC‐QTOF mass spectrometry (MS), and native protein MS with SARS‐CoV‐2 main protease as template. Ugi reactions were analyzed in aqueous buffer at varying pH and fragment concentration. Potent inhibitors of the protease were formed in presence of the protein via Ugi 4CR together with Ugi three‐component reaction (Ugi 3CR) products. Binding of inhibitors to the protease was confirmed by native MS and resulted in the dimerization of the protein target. Formation of Ugi products was, however, more efficient in the non‐templated reaction, apparently due to interactions of the protein with the isocyanide and imine fragments. Consequently, in‐situ ligation screening of Ugi 4CR products was identified as a superior approach to the discovery of SARS‐CoV‐2 protease inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Coronavirus 3C ProteasesCyanidesEndopeptidasesProtease Inhibitors

Stichwörter der Autor:innen

SARS-CoV-2 main proteaseUgi reactionantiviral agentsmulticomponent reactionsprotein-templated reactions

Substanzen

3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesCyanidesEndopeptidasesProtease Inhibitors

Autor:innen und Institutionen

  • Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str.2+4, 14195, Berlin, Germany.
  • Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Freie Universität Berlin, Thielallee 63, 14195, Berlin, Germany.

ORCID-Profile: Jörg Rademann

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Wamser, R., Zhang, X., Kuropka, B., Arkona, C., & Rademann, J. (2024). Protein‐Templated Ugi Reactions versus In‐Situ Ligation Screening: Two Roads to the Identification of SARS‐CoV‐2 Main Protease Inhibitors. Chemistry – A European Journal. https://doi.org/10.1002/chem.202303940

Vancouver

Wamser R, Zhang X, Kuropka B, Arkona C, Rademann J. Protein‐Templated Ugi Reactions versus In‐Situ Ligation Screening: Two Roads to the Identification of SARS‐CoV‐2 Main Protease Inhibitors. Chemistry – A European Journal. 2024. doi:10.1002/chem.202303940

BibTeX
@article{Wamser2024,
  author = {Wamser, Rebekka and Zhang, Xinting and Kuropka, Benno and Arkona, Christoph and Rademann, Jörg},
  title = {Protein‐Templated Ugi Reactions versus In‐Situ Ligation Screening: Two Roads to the Identification of SARS‐CoV‐2 Main Protease Inhibitors},
  journal = {Chemistry – A European Journal},
  year = {2024},
  doi = {10.1002/chem.202303940}
}
Kostenlos starten →